Abivax (NASDAQ:ABVX) Shares Gap Up – Should You Buy?

Abivax SA Sponsored ADR (NASDAQ:ABVX)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $114.94, but opened at $136.99. Abivax shares last traded at $133.9820, with a volume of 935,358 shares changing hands.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABVX. Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Morgan Stanley increased their price target on shares of Abivax from $71.00 to $101.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Truist Financial set a $140.00 price objective on shares of Abivax in a report on Monday, November 24th. BTIG Research upped their price objective on Abivax from $112.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Finally, Barclays started coverage on Abivax in a report on Monday, October 13th. They issued an “overweight” rating and a $142.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $128.73.

Abivax Stock Up 6.0%

The business has a 50-day moving average price of $110.40 and a 200 day moving average price of $74.15. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $11.43 billion, a P/E ratio of -84.78 and a beta of 0.48.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. On average, equities analysts expect that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Institutional Trading of Abivax

Large investors have recently bought and sold shares of the stock. Kennedy Capital Management LLC raised its position in Abivax by 7.1% during the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after acquiring an additional 15,997 shares during the period. Quadrature Capital Ltd acquired a new stake in Abivax in the 2nd quarter worth about $148,000. Octagon Capital Advisors LP purchased a new position in shares of Abivax in the first quarter valued at approximately $7,688,000. Saturn V Capital Management LP boosted its stake in shares of Abivax by 12.6% in the second quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock worth $4,762,000 after acquiring an additional 69,553 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Abivax during the first quarter worth approximately $1,250,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.